Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease
2022 · Scientific Reports · 4 citations
https://doi.org/10.1038/s41598-022-18354-x